ArticleImmunity, inflammation and disease2026
Bioinformatics-Driven Design of Fusion Recombinant Protein (EgFABP1-EgTeg) for Enhanced Immunodiagnosis of Hydatid Cysts.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHydatid cyst disease is caused by the parasite Echinococcus and poses significant health concerns worldwide. Due to the lack of early symptoms and limited diagnostic tools, researchers aim to design a more specific and sensitive antigen. The study focuses on developing a recombinant multi-epitope antigen using two parasite proteins (EgTeg and EgFABP1) and the IH4 nanobody.
methodsProtein sequences were analyzed and validated using bioinformatics tools, and B-cell epitopes were identified. The resulting antigen, confirmed by UniProt, is 266 amino acids long.
resultsThe multi-epitope antigen lacks a signal peptide and contains 46 phosphorylation sites associated with serine and tyrosine. Structural predictions showed both alpha helices and beta sheets in the secondary structure, with a spherical tertiary structure. Both linear and discontinuous epitopes were predicted, indicating regions with potential to stimulate immune responses. The antigen's physicochemical properties-molecular weight, isoelectric point stability index, and hydrophilicity-indicate that it is stable and suitable for diagnostic use.
conclusionsThe study introduces the EgFABP1-EgTeg-IH4 recombinant protein as a promising candidate for diagnosing HC disease. By integrating multiple antigenic regions and the IH4 nanobody, this approach significantly improves diagnostic specificity and sensitivity, offering the potential for more accurate, earlier detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.